Friedreich's Ataxia News and Research

RSS
Friedreich's ataxia is an inherited disease that causes progressive damage to the nervous system resulting in symptoms ranging from gait disturbance and speech problems to heart disease. A well-known celebrity afflicted with Friedreich's ataxia is former major leaguer and noted historian Clinton Stewart.
Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma to acquire Meritage

ViroPharma to acquire Meritage

UPC develops active knee-ankle orthosis to assist gait in people with incomplete SCI

UPC develops active knee-ankle orthosis to assist gait in people with incomplete SCI

FARA announces 2011 Ataxian Athlete Initiative grant recipients

FARA announces 2011 Ataxian Athlete Initiative grant recipients

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen first quarter total revenue increases 9% to $7,654,000

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Scripps Research receives CIRM grant for new research in stem cell biology and disease origins

Scripps Research receives CIRM grant for new research in stem cell biology and disease origins

Repligen anticipates 30% increase in total revenues for 2011

Repligen anticipates 30% increase in total revenues for 2011

USPTO grants new patent to Intellect's Alzheimer's vaccine

USPTO grants new patent to Intellect's Alzheimer's vaccine

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen third quarter total revenue increases 26% to $7,068,000

Scientists develop Australia's first pluripotent stem cell lines using skin biopsies for FA disease

Scientists develop Australia's first pluripotent stem cell lines using skin biopsies for FA disease

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

New findings could help scientists devise optimal therapies for Friedreich's ataxia

New findings could help scientists devise optimal therapies for Friedreich's ataxia